Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting
Authors
Keywords
-
Journal
Clinical & Translational Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-28
DOI
10.1007/s12094-020-02473-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older
- (2020) Jonathan D. Mizrahi et al. PANCREATOLOGY
- Some unanswered questions about older adults with metastatic pancreatic cancer
- (2020) Ana Ruiz-Casado et al. Journal of Geriatric Oncology
- Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
- (2019) Ursula M. Vogl et al. BMC CANCER
- Time to initial cancer treatment in the United States and association with survival over time: An observational study
- (2019) Alok A. Khorana et al. PLoS One
- Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
- (2019) Ayhan Ulusakarya et al. MEDICINE
- Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
- (2019) Sara Pusceddu et al. Cancers
- Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel
- (2019) Neha Papneja et al. PANCREAS
- Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
- (2019) Anouk E.J. Latenstein et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
- (2018) Mashaal Dhir et al. ANNALS OF SURGICAL ONCOLOGY
- Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates
- (2018) Pamela Minicozzi et al. Cancer Epidemiology
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
- (2018) Rossella De Luca et al. Drug Design Development and Therapy
- Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study
- (2018) Ana Fernández et al. BMC CANCER
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
- (2018) Muhammad Ahsan Javed et al. PANCREATOLOGY
- Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
- (2018) Moon Jae Chung et al. World Journal of Gastrointestinal Oncology
- Trends in net survival from pancreatic cancer in six European Latin countries
- (2017) Anne-Marie Bouvier et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Patterns of Chemotherapy Use in a U.S.‐Based Cohort of Patients with Metastatic Pancreatic Cancer
- (2017) Thomas A. Abrams et al. ONCOLOGIST
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary
- (2017) Davendra P.S. Sohal et al. Journal of Oncology Practice
- Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
- (2014) Gillian K Gresham et al. BMC CANCER
- A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
- (2014) Kelvin Chan et al. PLoS One
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started